Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827716) titled 'A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis' on Sept. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chuan Qin
Condition:
Relapsing Remitting Multiple Sclerosis
Intervention:
Drug: Terfenadine
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 15, 2026
Target Sample Size: 100
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study...